Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

Predictors of persistent high disease activity after methotrexate treatment in rheumatoid arthritis patients

Universa Medicina · Vol. 44 No. 2 (2025) · hlm. 141–151

DOI
10.18051/UnivMed.2025.v44.141-151
ISSN
2407-2230, 1907-3062
Terbit
2025-07-04
Penerbit
Faculty of Medicine, Universitas Trisakti
Bahasa
eng
Lisensi
creativecommons.org/licenses/by-nc-sa/4.0

Abstrak

Background Methotrexate (MTX) is the firstline therapy for rheumatoid arthritis (RA). However, 30–40% of RA patients exhibit poor response. Identifying early factors associated with persistent disease activity is critical to guide treatment. This study aimed to identify predictors of persistent high disease activity (DAS28-ESR >3.2) after six months of MTX therapy in RA patients. Methods A retrospective cohort study was conducted involving 204 RA patients who had completed six months of MTX therapy. The primary outcome was DAS28-ESR score at six months. Independent variables included baseline erythrocyte sedimentation rate (ESR), cumulative doses of MTX and low-dose methylprednisolone (LDM), and rheumatoid factor (RF) status. Simple and multiple logistic regression was used to analyze the data. Results Significant differences in ESR and cumulative MTX dose were observed between low and high disease activity groups. Multivariate analysis identified four independent predictors of persistent high disease activity (DAS28-ESR >3.2) after six months of MTX therapy: disease duration >11 months (AOR =0.45; 95% CI 0.23–0.89; p=0.025); age at onset >50 years (AOR 0.48; 95% CI 0.24–0.94; p=0.038); cumulative MTX dose >85 mg (AOR 4.75; 95% CI 1.55–14.64; p=0.006); ESR >66 mm/hr (AOR 2.32; 95% CI 1.11–4.89; p=0.026). Conclusion Greater cumulative methotrexate dose (>85 mg) was the most influential predictor of persistent high disease activity (DAS28-ESR >3.2) after six months of MTX therapy in RA patients. These findings may assist clinicians in identifying patients at risk for poor MTX response and support timely therapeutic adjustments.

Kata kunci

Jaringan kolaborasi para penulis

11 penulis · 22 tautan kepenulisan bersama · 11 lintas organisasi

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Universitas Gadjah Mada
  • Rumah Sakit Umum Pusat Dr. Sardjito
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Wasilah RochmahUniversitas Gadjah Mada1
Ahmad Husain AsdieUniversitas Gadjah Mada1
M. MarsetyawanUniversitas Gadjah Mada1
Sri SetiyariniUniversitas Gadjah Mada1
Probosuseno ProbosusenoRumah Sakit Umum Pusat Dr. Sardjito1
Sugeng SugengUniversitas Gadjah Mada1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) https://univmed.org/ejurnal/index.php/medicina/oai, pertama di-harvest 10 Nov 2026, terakhir terlihat 16 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Predictors of persistent high disease activity after methotrexate treatment in rheumatoid arthritis patients</dc:title>
	<dc:creator xml:lang="en">Paramaiswari, Ayu </dc:creator>
	<dc:creator xml:lang="en">Kertia, Nyoman </dc:creator>
	<dc:creator xml:lang="en">Achadiono, Deddy </dc:creator>
	<dc:creator xml:lang="en">Sinarta, Armin </dc:creator>
	<dc:creator xml:lang="en">Nugroho, Dhite</dc:creator>
	<dc:subject xml:lang="en">Persistent disease activity</dc:subject>
	<dc:subject xml:lang="en">rheumatoid arthritis</dc:subject>
	<dc:subject xml:lang="en">methotrexate</dc:subject>
	<dc:subject xml:lang="en">DAS28-ESR</dc:subject>
	<dc:subject xml:lang="en">predictors</dc:subject>
	<dc:description xml:lang="en">Background
Methotrexate (MTX) is the firstline therapy for rheumatoid arthritis (RA). However, 30–40% of RA patients exhibit poor response. Identifying early factors associated with persistent disease activity is critical to guide treatment. This study aimed to identify predictors of persistent high disease activity (DAS28-ESR &amp;gt;3.2) after six months of MTX therapy in RA patients.
Methods 
A retrospective cohort study was conducted involving 204 RA patients who had completed six months of MTX therapy. The primary outcome was DAS28-ESR score at six months. Independent variables included baseline erythrocyte sedimentation rate (ESR), cumulative doses of MTX and low-dose methylprednisolone (LDM), and rheumatoid factor (RF) status. Simple and multiple logistic regression was used to analyze the data.
 Results 
Significant differences in ESR and cumulative MTX dose were observed between low and high disease activity groups. Multivariate analysis identified four independent predictors of persistent high disease activity (DAS28-ESR &amp;gt;3.2) after six months of MTX therapy: disease duration &amp;gt;11 months (AOR =0.45; 95% CI 0.23–0.89; p=0.025); age at onset &amp;gt;50 years (AOR 0.48; 95% CI 0.24–0.94; p=0.038); cumulative MTX dose &amp;gt;85 mg (AOR 4.75; 95% CI 1.55–14.64; p=0.006); ESR &amp;gt;66 mm/hr (AOR 2.32; 95% CI 1.11–4.89; p=0.026).
 Conclusion 
Greater cumulative methotrexate dose (&amp;gt;85 mg) was the most influential predictor of persistent high disease activity (DAS28-ESR &amp;gt;3.2) after six months of MTX therapy in RA patients. These findings may assist clinicians in identifying patients at risk for poor MTX response and support timely therapeutic adjustments.</dc:description>
	<dc:publisher xml:lang="en">Faculty of Medicine, Universitas Trisakti</dc:publisher>
	<dc:date>2025-07-04</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://univmed.org/ejurnal/index.php/medicina/article/view/1754</dc:identifier>
	<dc:identifier>10.18051/UnivMed.2025.v44.141-151</dc:identifier>
	<dc:source xml:lang="en">Universa Medicina; Vol. 44 No. 2 (2025); 141-151</dc:source>
	<dc:source>2407-2230</dc:source>
	<dc:source>1907-3062</dc:source>
	<dc:source>10.18051/UnivMed.2025.v44.i2</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://univmed.org/ejurnal/index.php/medicina/article/view/1754/825</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2025 Ayu  Paramaiswari, Nyoman  Kertia, Deddy  Achadiono, Armin  Sinarta, Dhite Nugroho</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc-sa/4.0</dc:rights>
</oai_dc:dc>